Terazosin
- Generic Name
- Terazosin
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C19H25N5O4
- CAS Number
- 63590-64-7
- Unique Ingredient Identifier
- 8L5014XET7
- Background
Terazosin is a quinazoline derivative alpha-1-selective adrenergic blocking agent indicated for benign prostatic hyperplasia and hypertension. Terazosin blocks adrenaline's action on alpha-1 adrenergic receptors, causing relaxation of smooth muscle in blood vessels and the prostate.
- Indication
Terazosin is indicated for use in treating symptomatic benign prostatic hyperplasia and hypertension.
- Associated Conditions
- Benign Prostatic Hyperplasia (BPH), Hypertension, Ureteral Calculus
- Associated Therapies
- -
Motor Function Efficacy of Pharmacological Treatments Targeting Energy Metabolism, in Parkinson's Patients
- Conditions
- Interventions
- First Posted Date
- 2023-05-11
- Last Posted Date
- 2023-09-22
- Lead Sponsor
- I.R.C.C.S. Fondazione Santa Lucia
- Target Recruit Count
- 50
- Registration Number
- NCT05855577
Target Engagement of Terazosin in Healthy Adults
- First Posted Date
- 2020-09-16
- Last Posted Date
- 2023-12-06
- Lead Sponsor
- University of Iowa
- Target Recruit Count
- 18
- Registration Number
- NCT04551040
- Locations
- 🇺🇸
University of Iowa Hospitals and Clinics, Iowa City, Iowa, United States
Terazosin Effect on Cardiac Changes in Early Parkinson's Disease
- Conditions
- Interventions
- First Posted Date
- 2020-05-13
- Last Posted Date
- 2024-11-26
- Lead Sponsor
- Cedars-Sinai Medical Center
- Target Recruit Count
- 15
- Registration Number
- NCT04386317
- Locations
- 🇺🇸
Michele L Lima Gregorio, Los Angeles, California, United States
Safety and Efficacy of Low Dosage of Terazosin in Subjects Undergoing Carotid Artery Stenting
- Conditions
- Interventions
- First Posted Date
- 2017-06-22
- Last Posted Date
- 2018-12-11
- Lead Sponsor
- Capital Medical University
- Target Recruit Count
- 160
- Registration Number
- NCT03195673
- Locations
- 🇨🇳
The Luhe Teaching Hospital of the Capital Medical University, Beijing, Beijing, China
🇨🇳Beijing Anzhen Hospital, Beijing, Beijing, China
The Effect of Terazosin and Tolterodine on Ureteral Stent Related Symptoms
- Conditions
- Interventions
- First Posted Date
- 2012-02-09
- Last Posted Date
- 2015-03-02
- Lead Sponsor
- Urmia University of Medical Sciences
- Target Recruit Count
- 104
- Registration Number
- NCT01530243
- Locations
- 🇮🇷
Imam Khomeini Hospital, Urmia, Azerbaijan-gharbi, Iran, Islamic Republic of
Diesel Exhaust and Vascular Function
- Conditions
- Interventions
- First Posted Date
- 2012-01-12
- Last Posted Date
- 2015-08-03
- Lead Sponsor
- University of Washington
- Target Recruit Count
- 24
- Registration Number
- NCT01508637
- Locations
- 🇺🇸
University of Washington Medical Center, Seattle, Washington, United States
Effect of Amlodipine Monotherapy or Combined With Terazosin on Lower Urinary Tract Symptoms and Hypertension
- Conditions
- Interventions
- First Posted Date
- 2008-06-06
- Last Posted Date
- 2008-08-08
- Lead Sponsor
- Anhui Medical University
- Target Recruit Count
- 360
- Registration Number
- NCT00693199
- Locations
- 🇨🇳
Biomedicine Inistitute of Anhui Medical University, Hefei, Anhui, China
Excessive Sweating Caused by Antidepressants: Measurement and Treatment With Terazosin
- First Posted Date
- 2007-03-20
- Last Posted Date
- 2016-08-25
- Lead Sponsor
- Thomas Jefferson University
- Target Recruit Count
- 23
- Registration Number
- NCT00449683
- Locations
- 🇺🇸
Thomas Jefferson University, Department of Psychiatry, Philadelphia, Pennsylvania, United States
Pilot Study of Terazosin in Treatment of Antidepressant Induced Excessive Sweating
- Conditions
- First Posted Date
- 2005-10-12
- Last Posted Date
- 2014-03-05
- Lead Sponsor
- Thomas Jefferson University
- Target Recruit Count
- 15
- Registration Number
- NCT00237510
- Locations
- 🇺🇸
Thomas Jefferson University Department of Psychiatry and Human Behavior, Philadelphia, Pennsylvania, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.